Medicus Pharma Reports Positive Phase 2 Results for Skin Cancer Treatment

Key Facts

1Medicus Pharma reported positive Phase 2 clinical trial results for its microneedle-based treatment for basal cell carcinoma.

2The highest-dose group in the study achieved a 73% clinical clearance of lesions.

3The randomized, placebo-controlled study enrolled 90 patients with nodular basal cell carcinoma.

Medicus Pharma (NASDAQ: MDCX) has announced successful results from its Phase 2 clinical trial evaluating a non-invasive treatment for basal cell carcinoma. The study utilized a doxorubicin microneedle array (D-MNA) delivery system, representing a significant advancement in non-surgical chemotherapy. According to the report, the highest-dose group achieved a 73% clinical clearance rate of cancerous lesions. The randomized, placebo-controlled trial involved 90 patients suffering from nodular basal cell carcinoma to evaluate the efficacy of the treatment. These positive results mark a critical milestone for the biotech firm, potentially paving the way for future commercialization. Investors are closely monitoring the company as it moves closer to providing a viable alternative to traditional invasive procedures.